

## Bioethics Policy

### **R&D**

Research at Revvity is conducted responsibly and ethically with the intent to drive our mission of driving scientific innovation for the future. Ethical principles are the framework for all research activities throughout the company. Research is conducted in accordance with applicable laws and regulations, international guidelines, and ethical principles including but not limited to relevant ISO standards, Guiding Principles of Ethical Research (NIH), and EU Commission Ethics for Researchers. Fundamental to this approach are an ethical approach and discipline to Informed Consent, participant protection, confidentiality, and intellectual property.

### **Genetically Modified Organisms**

Revvity believes in ethical production and use of genetically modified organisms (GMO) & microorganisms (GMMO) to further science innovation and research. Utilizing GMO's and GMMO's to conduct ethical research and development plays a crucial role in product development for Revvity. All applicable laws, regulations, and best practices are followed regarding GMMO usage and transportation including but not limited to the Cartagena Protocol. Our ethical considerations include the evaluation of potential risks and benefits to human health and the environment with the goal of ensuring the use of any microorganisms is responsible, safe, and beneficial to society.

### **Stem Cells and Cord Blood**

Revvity develops advanced research tools to enable scientific innovation in a wide variety of applications for our customers. For specific applications, Revvity banks cord blood, utilizes iPSC (induced pluripotent stem cells), native stem cells, animal, and adult stem cells to advance development of emerging scientific innovation. Stem cells are used in research applications and with the highest ethical practices including following all applicable regulatory requirements to ensure safe and proper use, disposal, and consent. Revvity does not perform or fund research in human embryonic or fetal stem cells.

### **Maternal Fetal Health**

Revvity prioritizes the health and well-being of mothers and fetuses ensuring its products are safe and effective and do not pose harm. Its principles prioritize transparency and informed consent, responsibility for data management and security, and compliance with international, federal, and local laws and regulations.

### **Genome Editing**

Revvity products and services use genome editing both for product development and

to enable our customers to use our tools for genetic engineering and research using gene therapies. Revvity upholds and understands that basic and preclinical research using genome editing technologies of somatic cells and germline cells will follow appropriate international legal and ethical rules to further contribute to driving scientific innovation for a better future.

### **Genetic Information**

At Revvity we uphold the utmost ethical and social standards to ensure protection of privacy and autonomy, confidentiality, the accuracy and reliability of test results, the ethical use of genetic information, and security related to genetic information collected during research and development of products and services. All applicable international laws and regulations are followed and reviewed to ensure ethical practices within our laboratories.

### **Data Privacy and Patients' Right**

Revvity is committed to protecting data privacy and patients' rights as related to information gathered through scientific innovation, development, and research. Private data and patients' rights related to our services, research and development are protected and managed in accordance with applicable international, local, and federal privacy and data protection laws and with the utmost ethical principles.

### **Informed Consent**

Revvity recognizes the importance of patient autonomy. The Company is committed to obtaining informed consent prior to conducting any procedures or using/sharing personal health information. Revvity is committed to clear communication and transparency providing patients with information about their rights and options. The Company complies with applicable laws and regulations related to informed consent, including but not limited to FDA, HIPAA, GDPR, Good Clinical Practices (ICH-GCP), and the Declaration of Helsinki Ethical Guidelines and Principles.

### **Responsible use of New Technologies**

Development of new technologies is a key business driver value for Revvity. When dealing with the development of new technologies, PKI adheres to principles of 1) respect for patients' rights, safety, and well-being; 2) using new technologies based on sound scientific evidence, 3) compliance with laws; 4) Transparency about benefits, risks, and limitations and 5) continuous improvement.

This Bioethics policy/statement is updated as of May 9, 2023